Comparing SG&A Expenses: Pfizer Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Pharmaceutical Giants

In the world of pharmaceuticals, understanding the financial dynamics of companies is crucial. Over the past decade, Pfizer Inc. and Supernus Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Pfizer, a global leader, consistently reported SG&A expenses averaging around $14 billion annually, with a notable dip in 2020. This dip, approximately 20% from the previous year, reflects strategic cost management during the pandemic. In contrast, Supernus Pharmaceuticals, a smaller player, exhibited a remarkable growth trajectory. From 2014 to 2023, their SG&A expenses surged by over 360%, highlighting aggressive expansion and market penetration strategies. By 2023, Supernus's expenses reached nearly $336 million, a testament to their growing footprint. This comparison underscores the diverse strategies employed by pharmaceutical companies in navigating market challenges and opportunities.